Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
Study Details
Study Description
Brief Summary
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake.
The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the researchers will investigate individuals with and without intact nervous supply.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of intact vagal innervations on the effect of GLP-1 on the food intake, gastric emptying (GE) and appetite.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Vago Truncally vagotomized subjects (due to duodenal ulcer operation) |
Drug: GLP-1
1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
Other: Saline
Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
|
| Experimental: Cardia truncally vagotomized subjects (due to esophagus resection) |
Drug: GLP-1
1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
Other: Saline
Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
|
| Experimental: Healthy controls Healthy control subjects |
Drug: GLP-1
1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
Other: Saline
Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Gastric emptying [four hours]
Gastric emptying will be assessed using a liquid meal with 1.5 g paracetamol added and continuous blood sampling for measuring paracetamol concentration during four hours
- Appetite [four hours]
Hunger, satiation, and fullness will be assessed before, during and after a liquid meal with 1.5 g paracetamol added using a visual analog scale (VAS)
- Food intake [five hours]
After the liquid meal test, the volunteers will be offered a meal to assessed their ad libitum food intake
Secondary Outcome Measures
- plasma glucose [four hours]
- serum insulin and c-peptide [four hours]
- plasma glucagon [four hours]
- plasma GLP-1 [four hours]
- endogenous GLP-1 [four hours]
endogenous GLP-1 will be assessed as plasma GLP-2 concentration
- plasma GIP [four hours]
- serum paracetamol [four hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
truncal vagotomy
-
normal hemoglobin
-
informed consent
-
Age, gender and weight matched controls
-
normal hemoglobin
-
informed consent
Exclusion Criteria:
-
type 1 diabetes mellitus or type 2 diabetes mellitus
-
body mass index > 30 kg/m2
-
inflammatory bowel disease
-
intestinal resection
-
nephropathy (serum creatinine > 150 µM and/or albuminuria)
-
liver disease (ALAT and/or ASAT > 2 x normal value)
-
treatment with medicine which cannot be paused for 12 hours
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Internal Medicine F' laboratory | Hellerup | Copenhagen | Denmark | 2900 |
Sponsors and Collaborators
- University Hospital, Gentofte, Copenhagen
- University of Copenhagen
Investigators
- Principal Investigator: Astrid Plamboeck, M.D., University Hospital, Gentofte, Copenhagen
- Study Director: Tina Vilsbøll, M.D., University Hospital, Gentofte, Copenhagen
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Truncated mealtest (AP)